Jason Zemansky
Stock Analyst at B of A Securities
(4.87)
# 64
Out of 5,143 analysts
51
Total ratings
74.29%
Success rate
44.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $6 | $2.05 | +192.68% | 1 | Jan 21, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $15.52 | +22.42% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $20.19 | +28.78% | 6 | Nov 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $10 → $8 | $4.25 | +88.24% | 5 | Nov 18, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.66 | +958.04% | 6 | Nov 18, 2025 | |
| INSM Insmed | Maintains: Buy | $142 → $187 | $158.62 | +17.89% | 11 | Oct 27, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $70.10 | -20.11% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $30.88 | +0.39% | 4 | Apr 1, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $8.38 | +246.06% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $20.53 | +51.00% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $2.9 → $2.5 | $3.30 | -24.24% | 5 | Jun 20, 2024 |
Inhibikase Therapeutics
Jan 21, 2026
Initiates: Buy
Price Target: $6
Current: $2.05
Upside: +192.68%
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $15.52
Upside: +22.42%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $20.19
Upside: +28.78%
Rocket Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $4.25
Upside: +88.24%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.66
Upside: +958.04%
Insmed
Oct 27, 2025
Maintains: Buy
Price Target: $142 → $187
Current: $158.62
Upside: +17.89%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $70.10
Upside: -20.11%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $30.88
Upside: +0.39%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $8.38
Upside: +246.06%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $20.53
Upside: +51.00%
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $3.30
Upside: -24.24%